For US Healthcare Professionals only

Prescribing Information For Patients
Image of ABSSSI Patient 1

ABSSSI patient with renal insufficiency

Actor portrayal.

Back to Case Studies

Clinically cured* with a single course of oral NUZYRA1

*Clinical cure at the post-treatment evaluation was defined as survival after completion of study treatment without receiving any other antibacterial therapy or unplanned major surgical intervention, and having sufficient resolution of infection such that further antibacterial therapy is not needed.2

Before & After

Initial presentation

Before image of patient's skin showing initial presentation

Final healed wound at 2-week follow-up

After image of patient's skin showing the final healed wound at 2-week follow-up

Patient Overview

50-year-old female hospitalized for skin infection

  • Abscess, cellulitis, and confirmed MRSA
  • History of multiple comorbidities, including reduced renal function
  • Inpatient care setting

Clinical Course

Day
1

Hospitalized and started on IV vancomycin and ceftriaxone

Day
2

Ceftriaxone discontinued upon culture result—MRSA with vancomycin MIC 0.5 mg/mL

Day
3

Transitioned to IV NUZYRA 450 mg PO loading dose for 2 days

Day
4

Discharged with oral NUZYRA 300 mg daily

Day
14

Cellulitis was resolved and patient remained pain-free
See additional medical findings

Laboratory findings1

  • WBC: 14.92 K/mm3
  • CRP: 4.7
  • CrCl: 37 mL/min

Exam findings and clinical course1

  • Fluctuance when palpated
  • Wound incised and drained
  • Culture confirmed MRSA
  • Negative for DVT
  • Temperature 97.6°F
CrCl=creatinine clearance; CRP=C-reactive protein; DVT=deep vein thrombosis; IV=intravenous; MIC=minimum inhibitory concentration; MRSA=methicillin-resistant Staphylococcus aureus; PO=per os; WBC=white blood cell count.

This case study reflects a real patient experience using NUZYRA. The results presented are consistent with those observed in the OASIS-2 clinical trial in patients with ABSSSI. Individual results may vary.

Back to Case Studies
IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

NUZYRA® is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:

Community-Acquired Bacterial Pneumonia (CABP) caused by the following: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.

USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients.

WARNINGS AND PRECAUTIONS

Permanent tooth discoloration and enamel hypoplasia may occur with the use of NUZYRA during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years).

Reversible inhibition of bone growth may occur with the use of NUZYRA during the second and third trimester of pregnancy, infancy, and childhood up to the age of 8 years.

Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline class antibacterial drugs. NUZYRA is structurally similar to other tetracycline class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

Tetracycline class effects may occur with NUZYRA. Adverse reactions, including photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.

Risk of the development of drug-resistant bacteria is increased when prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication and is unlikely to provide benefit to the patient.

ADVERSE REACTIONS

CABP: The most common adverse reactions (incidence ≥2%) are alanine aminotransferase increased, headache, hypertension, and aspartate aminotransferase increased.

ABSSSI: The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, headache, and diarrhea.

DRUG INTERACTIONS

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.

Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations.

USE IN SPECIFIC POPULATIONS

Lactation: Breastfeeding is not recommended during treatment with NUZYRA.

Please see full Prescribing Information for NUZYRA.

References: 1. Data on file. Paratek Pharmaceuticals, Inc. 2. NUZYRA [Prescribing Information]. Paratek Pharmaceuticals, Inc.